Academic Journal

POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)

التفاصيل البيبلوغرافية
العنوان: POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
المؤلفون: Giralt, Sergio, Ailawadhi, Sikander, Arnulf, Bertrand, Patel, Krina, Cavo, Michele, Nooka, Ajay K., Manier, Salomon, Callander, Natalie, Costa, Luciano J., Vij, Ravi, Bahlis, Nizar J., Moreau, Philippe, Solomon, Scott R., Delforge, Michel, Berdeja, Jesús, Truppel-Hartmann, Anna, Yang, Zhihong, Favre-Kontula, Linda, Wu, Fan, Piasecki, Julia, Cook, Mark, Rodríguez-Otero, Paula
المصدر: Clinical Lymphoma Myeloma and Leukemia ; volume 23, page S232 ; ISSN 2152-2650
بيانات النشر: Elsevier BV
سنة النشر: 2023
المجموعة: ScienceDirect (Elsevier - Open Access Articles via Crossref)
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1016/s2152-2650(23)00909-6
الاتاحة: http://dx.doi.org/10.1016/s2152-2650(23)00909-6
https://api.elsevier.com/content/article/PII:S2152265023009096?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S2152265023009096?httpAccept=text/plain
Rights: https://www.elsevier.com/tdm/userlicense/1.0/
رقم الانضمام: edsbas.68DEC8FB
قاعدة البيانات: BASE
الوصف
DOI:10.1016/s2152-2650(23)00909-6